Home › Trials › NCT07319871
Clinical trial Recruiting at 5 sites Phase 1 Interventional Ages 18 and up

Pasritamig plus JNJ-86974680 for advanced prostate cancer

Official title: A Phase 1b Study of Pasritamig (JNJ-78278343), a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With JNJ-86974680, an A2a Receptor (A2aR) Antagonist, for Prostate Cancer

Run by Janssen Research & Development, LLC · NCT07319871 · Data updated 2026-11-12

This trial will test whether combining pasritamig with JNJ-86974680 is safe and to find the best dose for people with metastatic castration-resistant prostate cancer.

Quick facts

PhasePhase 1
Study typeInterventional
Ages18 Years and up
SexAll
Enrollment40 (estimated)
SponsorJanssen Research & Development, LLC
Industry-sponsored
Locations5 sites (Sarasota, Florida and 4 other locations)
StatusRecruiting
StartedJanuary 14, 2026
Main results expectedJanuary 7, 2027
Study endsMarch 15, 2028
Registry record updatedNovember 3, 2026
Trial IDNCT07319871 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Men with histologically confirmed metastatic castration-resistant prostate adenocarcinoma who are on continuous androgen deprivation therapy and meet other health criteria are the intended candidates.

Probably not a fit

Patients with primary neuroendocrine prostate cancers, significant visceral metastases, or who are not on required androgen deprivation therapy are unlikely to qualify or benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, two-part dose-finding and dose-expansion trial of pasritamig combined with JNJ-86974680 in participants with advanced prostate adenocarcinoma. Part 1 uses escalating doses to identify a recommended Phase 2 combination dose (RP2CD), and Part 2 gives that dose to more participants to characterize safety and tolerability. Eligible participants must have metastatic castration-resistant prostate cancer and remain on androgen deprivation therapy during treatment. The trial is being conducted at multiple U.S. cancer centers and is sponsored by Janssen Research & Development.

Why it matters

Potential benefit: If successful, the combination could offer a new treatment option that better controls disease or delays progression in some men with advanced prostate cancer.

How similar studies have gone: This specific combination is early-phase and relatively novel, and while other targeted drug combinations have shown promise in early trials, there is limited prior data on these two agents together.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologically confirmed adenocarcinoma of the prostate. Primary small cell carcinoma, carcinoid tumor, neuroendocrine (NE) carcinoma, or large cell NE carcinoma arising in the prostate are not allowed; however, adenocarcinomas with NE features (for example \[e.g.\], immunohistochemistry \[IHC\] with both androgen receptor \[AR\]- and NE-marker positivity) are allowed
* Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs. Local-regional invasion (rectum, bladder) and bone disease with soft tissue component can be included
* Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone \[GnRH\] analog \[agonist or antagonist\] prior to the first dose of study drug and must continue this therapy throughout the treatment phase)
* Prostate-specific antigen (PSA) greater than or equal to (\>=) 2 nanograms per milliliters (ng/mL) at screening
* Measurable or evaluable disease
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion criteria:

* Toxicity related to prior anticancer therapy that has not returned to grade less than or equal to (\<=) 1 or baseline levels (except for alopecia, neuropathy \[Grade 2\] and vitiligo)
* Known allergies, hypersensitivity, or intolerance to any of the components (for example, excipients) of pasritamig or JNJ-86974680
* Active infection or condition that requires treatment with systemic antibiotics within 7 days prior to the first dose of study treatment. Antibiotic or antiviral prophylaxis is allowed
* Have leptomeningeal disease or brain metastases, except participants with definitively, locally treated brain metastases that are clinically stable and asymptomatic \>2 weeks, and who are off corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
* Any serious underlying medical conditions or other issue that would impair the ability of the participant to receive or tolerate the planned treatment at the investigational site to understand the informed consent, or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments

Where it's running

  • Florida Cancer Specialists
    Sarasota, Florida, United States     Recruiting
  • Columbia University Medical Center
    New York, New York, United States     Recruiting
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio, United States     Recruiting
  • The Christie NHS Foundation Trust Christie Hospital
    Manchester, United Kingdom     Recruiting
  • Royal Marsden Hospital
    Sutton, United Kingdom     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostatic Neoplasms 37Janssen Research & Development, LLC 73
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.